Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.
Publication
, Conference
Li, EC; Mezzio, D; Campbell, KJ; Spargo, A; Lyman, GH
Published in: JOURNAL OF CLINICAL ONCOLOGY
2020
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
29
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Li, E. C., Mezzio, D., Campbell, K. J., Spargo, A., & Lyman, G. H. (2020). Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 38).
Li, Edward C., Dylan Mezzio, Kimberley J. Campbell, Andrew Spargo, and Gary H. Lyman. “Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 38, 2020.
Li EC, Mezzio D, Campbell KJ, Spargo A, Lyman GH. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk. In: JOURNAL OF CLINICAL ONCOLOGY. 2020.
Li, Edward C., et al. “Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.” JOURNAL OF CLINICAL ONCOLOGY, vol. 38, no. 29, 2020.
Li EC, Mezzio D, Campbell KJ, Spargo A, Lyman GH. Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk. JOURNAL OF CLINICAL ONCOLOGY. 2020.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2020
Volume
38
Issue
29
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences